top of page

5 new projects will be supported by the PSCC


We are delighted to announce that 5 new projects have been selected by the Paris-Saclay Cancer Paris (PSCC) to benefit from its support: BlueBees, Klineo, Inen Robotics, Biogenera and a start-up in creation.


This month's shortlist highlights groundbreaking innovations in biotechnology, digital health, and medical devices, with a focus on improving oncology treatment and care.


  • BlueBees develops first-in-class immunotherapies for the treatment of cancer based on disruptive technology that potentiates the ability of antibodies to activate immune cells.

  • Klineo offers a digital health platform enabling intuitive, intelligent and rapid research of clinical trials, thereby facilitating patient access to new therapeutic options.

  • Inen Robotics creates robotic solutions for gastroenterology operations, enabling precise interventions to be performed while reducing the risk of complications.

  • Biogenera specializes in the research and development of personalized DNA-based biotechnology medicines. Their exclusive MyGeneraTM platform identifies and develops molecules specifically targeting mutated genes responsible for diseases, with a first product in pediatric oncology targeting the MYCN gene.


In addition to these projects, we are also delighted to support a start-up in creation, the details of which will be revealed soon. These developments represent a promising leap forward in the field of oncology and are expected to improve patient care and outcomes.


With 44 cutting-edge oncology projects selected and supported, PSCC offers the most promising developers access to a comprehensive set of resources to accelerate oncology innovation: expertise, networking, funding, data, samples, technologies , infrastructure, training, laboratories.


Are you developing an innovative solution for oncology patients? Join us: https://www.parissaclaycancercluster.org/en/postulez

Comments


bottom of page